BJDX News and Press, Bluejay Diagnostics Inc.

ACTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid near-patient tests to improve patient outcomes in critical care settings, today provided a corporate...

ACTON, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ: BJDX) today announced that as of February 19, 2026, all of the prefunded warrants issued by the Company in its October 2025 private placement have been fully exercised, and the Company has no remaining prefunded warrants...

ACTON, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ: BJDX) today announced that it has successfully enrolled 545 patients in its SYMON™ II multicenter clinical study and has made substantial progress in advancing manufacturing readiness and technology transfer initi...

2026-01-27 08:10:41 ET More on Bluejay Diagnostics Seeking Alpha’s Quant Rating on Bluejay Diagnostics Financial information for Bluejay Diagnostics Read the full article on Seeking Alpha For further details see: Bluejay Diagnostics announces 1-for...

ACTON, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announ...

ACTON, Mass., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”) announced that it has completed commercial-scale production of both polyclonal and monoclonal antibodies targeting interleukin-6 (IL-6), a biomarker re...

Company focused on advancing clinical milestones and strategic partnerships, with goal of positioning itself for future FDA clearance and product commercialization. Patient enrollment in SYMON-II clinical trial now approximately 50% completed. Recent private placement transaction ...

2025-10-23 17:07:47 ET More on Bluejay Diagnostics Financial information for Bluejay Diagnostics Read the full article on Seeking Alpha For further details see: Bluejay Diagnostics files to sell 6.93M shares of common stock for holders

ACTON, Mass., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing near-patient solutions for critical care, today announced the closing of its previously announced private pla...

A look at the top 10 most actives in the United States AiRWA Inc. (YYAI) rose 8.3% to $0.209 on volume of 775,237,685 shares EPWK Holdings Ltd. (EPWK) rose 52.5% to $0.1148 on volume of 756,638,089 shares AtlasClear Holdings Inc. (ATCH) rose 37.6% to $0.5 on volume of 420,835,167 shares N...